Geographically, North America commands largest share of cardiac marker testing market in 2016, followed by Europe. Factors such as growing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers and ongoing clinical trials for identification of novel cardiac biomarkers are fueling growth of cardiac marker testing market.
Complete details on this report “Cardiac Marker Testing Market” spread across 159 Pages, Profiling 11 Companies and Supported with 110 Tables and 33 Figures is now available at www.reportsnreports.com/reports/72…t-st-to-2021.html .
North America held the largest share of global cardiac marker testing market, followed by Europe. However, Asia-Pacific market expected to register the highest CAGR of 11.7% from 2016 to 2021.
Factors such as rising prevalence and incidence of cardiovascular diseases and public-private initiatives to increase awareness about early cardiac disease diagnosis are stimulating growth of cardiac marker testing market in Asia-Pacific region.
Report Focuses on Following Stakeholders
- Biomarkers assays and reagents manufacturers, vendors, and distributors
- Contract research organizations (CROs)
- Diagnostic kit manufacturing companies
- Imaging instrument providers
- Market research and consulting firms
- Pharmaceutical companies
Emerging markets, including India and China, have become attractive destinations for companies engaged in the development and marketing of cardiac biomarkers. Rising prevalence and incidence of cardiovascular diseases is among the major driving factors for the growth of this market in China and India.
For instance, annual cardiovascular events in China were projected to increase by more than 50% from 2010 to 2030.
The global cardiac marker testing technology market segmented on basis of type of testing into laboratory testing and point-of-care testing. Point-of-care testing segment is fastest-growing segment in this market owing to advantages offered by it (such as reductions in length of stay, improved emergency department efficiency, increased patient satisfaction and user experience, better turnaround times.
1 Global Cardiac Marker Testing Market Overview
2 Geographic Analysis: Cardiac Marker Testing Market, By Technology,
3 Market Size, By Type,
4 Market, By Product,
5 Geographical Snapshot of the Market,
6 Life Cycle Analysis, By Region
Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd.
(Wondfo) (China) are some of the key players operating in the global cardiac marker testing market.
North America is expected to account for the largest share of the global cardiac marker testing market in 2016, followed by Europe and Asia-Pacific. The Asia-Pacific market is expected to register the highest CAGR during the forecast period.
The high growth in this segment can be attributed to rising prevalence and incidence of cardiovascular diseases, public–private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians, and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars in the region.